149771-08-4

Usage

Uses

Used in Pharmaceutical Industry:
Diethyl 2-(Methylthio)-4,5-pyrimidinedicarboxylate is used as an HIV integrase inhibitor for its ability to interfere with the integration of the HIV virus into the host genome, thereby inhibiting the replication and spread of the virus within the human body. This application is particularly relevant in the development of antiretroviral therapies to combat HIV/AIDS.

InChI:InChI=1/C11H14N2O4S/c1-4-16-9(14)7-6-12-11(18-3)13-8(7)10(15)17-5-2/h6H,4-5H2,1-3H3

Upstream product

• 14527-26-5 2-methylisothiourea sulphate 
• 867-44-7 S-Methylisothiourea sulfate 
• 108-56-5 diethyl oxaloacetate 
• 5909-24-0 4-chloro-2-methanesulfanylpyrimidine-5-carboxylic acid ethyl ester 
• 64-17-5 ethanol 
• 201230-82-2 carbon monoxide 

Downstream Products

• 149771-16-4 2-methylthiopyrimidine-4,5-dicarboxylic acid 
• 294673-59-9 6-[3,5-bis(trifluoromethyl)phenyl]-2-methylthio-3-pyrrolino[3,4-d]pyrimidine-5,7-dione 
• 294673-60-2 6-{[3,5-bis(trifluoromethyl)phenyl]methyl}-2-methylthio-3-pyrrolino[3,4-d]pyrimidine-5,7-dione 

Relevant academic research and scientific papers

HIV INTEGRASE INHIBITORS

The present invention concerns the compounds having the formula (1), N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof wherein (a) or (b); A, together with the two carbons of the phenyl ring to which it is attached forms a monocyclic aryl or a monocyclic Het2 ; R1 is hydrogen, halo, nitro, cyano, sultam, sulltim, C3-7cycloalkyl, C(=O)-R5, S(=O)y-R6, OR 7, NR8R9, C(=NR8)-R5, optionally polysubstituted C1-6alkyl, optionally polysubstituted C2-6alkenyl or optionally polysubstituted C2-6alkynyl; R 2 is hydrogen, C3-7cycloalkyl, aryl, Het1, Het2, C(=O)-R5, S(=O)Y-R6 OR7, NR8R9, C=NR8)-R5, or optionally polysubstituted C1-6alkyl, optionally polysubstituted C2-6alkenyl or optionally polysubstituted C2-6alkynyl. It further relates to their use as HIV integrase inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. It also concerns combinations thereof with other anti-retroviral agents, and to their use in assays as reference compounds or as reagents.

Synthesis and structure-activity relationship studies of conformationally restricted, analogs of 2-chloro-4-trifluoromethylpyrimidine- 5-[N-(3',5'-bis(trifluoromethyl)phenyl)]carboxamide

2-Chloro-4-trifluoromethylpyrimidine-5-N[(3,5- bis(trifluoromethyl)phenyl] carboxamide (1) was identified as an inhibitor of AP-1 and NF-κB mediated transcriptional activation. In an effort to identify novel compounds that contain less number of trifluoromethyl groups with comparable potency as 1, several conformationally restricted analogs of I were synthesized in which the pyrimidine ring and the aniline ring were connected through a second 'bridge'. The 7-membered sulfur bridged analog was the most potent in this series, and comparable to 1 in activity.

Synthesis, antiviral (HSV-1) and antimycotic activities of ethyl or methyl 2,4-disubstituted 5-pyrimidinecarboxylates, 2,4-disubstituted 5-pyrimidinecarboxylic acids and 2,4-disubstituted pyrimidines

The synthesis of ethyl or methyl 4-substituted or unsubstituted 2-methylthio-5-pyrimidinecarboxylates 3 a-i and 8 o mainly by reaction of ethyl or methyl 2-dimethylaminomethylene-3-oxoalkanoates with 2-methylisothiourea is described. Also some ethyl 2-sub